Topics

AbbVie's Venclyxto pins down CHMP approval for treatment-naive chronic lymphocytic leukaemia

05:29 EST 3 Feb 2020 | Pharmafile

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has awarded recommendation to AbbVie’s Venclyxto (venetoclax), it has emerged, in the treatment of previously untreated chronic lymphocytic leukaemia (CLL) when combined with obinutuzumab.

Phase 3 data submitted in support of the application showed that Venclyxto displayed “superior” benefit in progression-free survival compared to the standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil, meeting the study’s primary endpoint.

read more

Original Article: AbbVie's Venclyxto pins down CHMP approval for treatment-naive chronic lymphocytic leukaemia

NEXT ARTICLE

More From BioPortfolio on "AbbVie's Venclyxto pins down CHMP approval for treatment-naive chronic lymphocytic leukaemia"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...